Author: yourbiotech

The Rice Biotech Launch Pad accelerator was announced on the 61st anniversary of President John F. Kennedy’s moonshot speech. This initiative aims to develop new research and emerging technologies into practical clinical applications by bridging the gap between researchers, medical companies and healthcare professionals, Omid Veiseh said. Omid Veiseh, an associate professor in the department of bioengineering and a biotechnologies entrepreneur, serves as the faculty director of the Launch Pad. Veiseh said the Launch Pad will support new discoveries through navigating regulatory procedures, manufacturing and business development. “Our vision for this launch pad is to create the necessary infrastructure ……

Read More

1. Philanthropic disease foundations rival VCs in life sciences The third in the Business Journal’s three-part series on philanthropy and business focuses on disease foundations and venture capital. Nonprofit investors maintain that despite their similarities to venture capital firms, the model also has drawbacks, including misaligned incentives, reports Rowan Walrath. Scroll down for more. 2. At last: A biotech IPO Rowan also reports on a rarity for 2023: A biotech company just went public in a $250 million IPO, at a $2.7 billion valuation. 3. Cambridge Health Alliance to require masks starting today Cassie McGrath reports that Cambridge Health Alliance has reinstated its mask mandate for…

Read More

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA. Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment. The biotech, which is based in Somerville, Mass., has big plans for the next couple of…

Read More

When you think about Ghent, Belgium, do you think about its historic city centre, with the Castle of the Counts and its intricate network of canals and waterways? Sure, but do you also think about how it’s poised to become the European technology capital? Mixing excellent infrastructure, talented individuals working on the modern miracles of tomorrow, and fostering regular collaboration between research organizations and business solutions, one can witness the captivating and vibrant energy of this city. The proof of the pudding is in the eating and that’s also true for Ghent’s vibrant healthtech cluster. With seamless cooperation between life…

Read More

Montreal, the largest city in Canada’s Quebec province, has seen a boom in life sciences over the years. Home to The Biotech City, a hub that connects and supports biopharmaceutical companies within the region as well as attracts talent from across the world, Montreal rivals the likes of Vancouver and Toronto, in being the leading biotech hub in the country. As it contributes to 79% of Quebec’s gross domestic product (GDP), the second largest Canadian city has a competitive advantage in the life science sector due to its significant growth in areas such as pharmaceuticals, digital health, and artificial intelligence. The presence of…

Read More

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. Neumora is offering 14,710,000 shares at a range of $16 to $18 apiece, which would mean a raise of $250 million at the midpoint, according to a Monday regulatory filing. The biotech is seeking to list its shares under the ticker “NMRA.” The underwriters will have access to another 2,206,500 shares of common stock for 30 days. The neuroscience biotech is seeking a valuation of up to $2.74 billion based on the higher end of…

Read More

In this article, we discuss 12 biotech stocks with biggest upside. If you want to skip our detailed discussion on the recent developments in the biotech industry, you can go directly to 5 Biotech Stocks with Biggest Upside. According to Precedence Research, the size of the biotechnology industry stood at $1.22 trillion at the end of 2022. The industry is set to compound annually at an average rate of 12.8% to reach $3.21 trillion by 2030. Governments across the world are providing favorable initiatives to this industry, given its strong growth potential. The biotechnology industry owes much of its growth to biopharmacy,…

Read More

The Expedition 69 crew aboard the International Space Station focused its main research activities on biotechnology on Wednesday. The orbital residents also continued the ongoing maintenance of lab hardware. Researchers on the ground use the facilities aboard the space station to understand how living in weightlessness affects the human body. Some of the experiments operate remotely or autonomously, for others the astronauts set up and run the experiments, or even act as subjects as NASA and its international partners learn how to sustain crews on future missions to the Moon, Mars, and beyond. NASA Flight Engineer Jasmin Moghbeli began her day conducting DNA research by analyzing…

Read More

While it’s been a rocky year for many, everything is smooth sailing at Kriya Therapeutics—one of biotech’s top money raisers last year—as it continues its acquisition streak. This time, Kriya has snapped up Tramontane Therapeutics and will be developing a nonalcoholic steatohepatitis (NASH) program sourced from the gene therapy biotech. Kriya now wholly owns the Autonomous University of Barcelona (Universitat Autònoma de Barcelona, or UAB) spinout and its neurodegenerative- and metabolic-disease-focused portfolio of fibroblast growth factor 21 (FGF21) assets. Financial details of the deal were not disclosed. Tramontane’s lead program is an adeno-associated virus-vector-powered therapy made to express a consistent…

Read More

A memorandum of understanding (MOU) was signed on Tuesday between the Department of Biotechnology, Ministry of Science and Technology, and Armed Forces Medical Services (AFMS) to build research collaborations and promote scientific cooperation. The agreement was signed at the Armed Forces Medical College (AFMC) here in the presence of Minister of State (Independent Charge), Science & Technology, Jitendra Singh. The MOU also envisages promoting scientific cooperation through faculty exchange programmes. As part of the year-long platinum jubilee celebrations of the medical college, Singh also launched the Association of Physicians of India (API) chapter of AFMC, Pune, and also inaugurated the…

Read More